top of page
  • LinkedIn
  • White Facebook Icon
UTHPeak NMNH - A Potentially More Potent NAD+ Booster

The Age of
Super NAD+ Boosters
Has Arrived.

10

Times

 NAD+ SURGE

20

Hours

STEADY NAD+ BOOST

5

Organs

ANTI-AGING IMPACT

1

ST

GLOBAL CRYSTALLINE PATENT

What Is UthPeak™?

UthPeak™ NMNH (Reduced NMN) is a patent-pending crystalline NMNH, a reduced form of nicotinamide mononucleotide (NMN), a potentially more potent NAD+ booster than mainstream market-available NAD+ precursors. UthPeak™ is currently going through preclinical and clinical studies to validate its efficacy in supporting a wide range of health benefits.

NMNH: The Next-Gen NAD+ Enhancer, 5 Times More Potent Than NMN.

* Based on in vitro and in vivo test results

NMNH (Reduced NMN)

NMN

NAD+ RISE

10 Times

2 Times

PEAK LEVEL

20 Hrs

1 Hr

ORGAN IMPACT

Liver, Kidney

Brain, Heart, 

Gastrocnemius Muscle

UthPeak™ Clinical Agenda

2023

Toxicology Testing Completed

2024

Phase I - Clinical Trial

2025

Phase II - Clinical Trial

Currently, UthPeak™ NMNH (Reduced NMN) has completed 3 out of 5 pre-clinical studies, and there is a clearly defined clinical timeline to further verify its efficacy and safety. The upcoming UthPeak™ clinical trials will focus on assessing NMNH's potential in enhancing consumer-centric well-being factors, such as cardioprotection, energy enhancement, and liver protection observed in animal studies. 

Building on inferences from both in vitro and in vivo tests and the proven benefits of NAD+ boost, NMNH (Reduced NMN) shows the potential to offer multiple health benefits beyond the animal model. This will be the central focus of UthPeak™'s R&D efforts and the brand's investment in science.

Anti-Aging

Energy Boost

Cardiovascular Health Promoting

Weight Management

UthPeak™, A Patent-Pending Stabilized Form of NMNH (Reduced NMN)

With UthPeak™'s patented crystalline technology spanning 20 countries worldwide, prepare to strategize your brand and product offerings by harnessing the tomorrow's health ingredient ROCK STAR. Outshine your competitors by entering the new epoch of super NAD+ boosters.

Enquire a Sample Now

What EffePharm R&D Director Says About UthPeak™?

Dr. Jianjun YU, EffePharm R&D Director

"We believe that NMNH (Reduced NMN) could be the next star NAD+ booster. We have observed a great deal of potential in this ingredient through animal models in the lab. If these benefits can be confirmed and extended to human beings, we stand to benefit significantly as an aging population. At EffePharm, we exclusively invest in cutting-edge ingredients with verified benefits because we believe in EFFECTIVE NUTRITION. This is what enables us to lead more fulfilling and creative lives. The global success of Uthever® has demonstrated that our efforts can profoundly impact consumers' lives. We are committed to continuing to create value for users of UthPeak™."

--- Dr. Jianjun YU, EffePharm R&D Director

Scientist on Tablet | UTHPeak

Be the first to know the latest update on UthPeak™ studies.

Thanks for submitting!

CONTACT

CONTACT US

EffePharm Ltd.

Thanks for submitting!

bottom of page